OBJECTIVE: Therapy with the retinoid X receptor agonist bexarotene is associated with hypothyroidism caused by decreased pituitary TSH secretion. To evaluate the effects of bexarotene on peripheral thyroid hormone metabolism, we performed a study in athyreotic subjects on a fixed substitution dose with L-T4. DESIGN: The design was an open prospective 6-wk intervention study. METHODS: Ten athyreotic patients with pulmonary metastases of differentiated thyroid carcinoma received 6-wk redifferentiation treatment with 300 mg bexarotene/d. L-T4 doses were kept stable. Before and in the sixth week of therapy, serum levels of total T4, free T4 (FT4), T3, reverse T3 (rT3), and TSH were measured. To study nondeiodinase-mediated thyroid hormone degradation, serum levels of T4 sulfate (T4S) were measured. Recombinant human TSH was administered before and in the sixth week of bexarotene therapy. RESULTS: Bexarotene induced profound decreases in total T4 (56% of baseline), FT4 (47%), T3 (69%), rT3 (51%), and T4S (70%) in all patients, whereas TSH levels were not affected. The T3/rT3 ratio increased by 43%, and the T4S/FT4 ratio increased by 48%. Serum TSH levels before and after recombinant human TSH were unaffected by bexarotene. CONCLUSIONS: In the present study, we demonstrate that increased peripheral degradation of thyroid hormones by a nondeiodinase-mediated pathway contributes to bexarotene induced-hypothyroidism.
OBJECTIVE: Therapy with the retinoid X receptor agonist bexarotene is associated with hypothyroidism caused by decreased pituitary TSH secretion. To evaluate the effects of bexarotene on peripheral thyroid hormone metabolism, we performed a study in athyreotic subjects on a fixed substitution dose with L-T4. DESIGN: The design was an open prospective 6-wk intervention study. METHODS: Ten athyreoticpatients with pulmonary metastases of differentiated thyroid carcinoma received 6-wk redifferentiation treatment with 300 mg bexarotene/d. L-T4 doses were kept stable. Before and in the sixth week of therapy, serum levels of total T4, free T4 (FT4), T3, reverse T3 (rT3), and TSH were measured. To study nondeiodinase-mediated thyroid hormone degradation, serum levels of T4 sulfate (T4S) were measured. Recombinant humanTSH was administered before and in the sixth week of bexarotene therapy. RESULTS:Bexarotene induced profound decreases in total T4 (56% of baseline), FT4 (47%), T3 (69%), rT3 (51%), and T4S (70%) in all patients, whereas TSH levels were not affected. The T3/rT3 ratio increased by 43%, and the T4S/FT4 ratio increased by 48%. Serum TSH levels before and after recombinant humanTSH were unaffected by bexarotene. CONCLUSIONS: In the present study, we demonstrate that increased peripheral degradation of thyroid hormones by a nondeiodinase-mediated pathway contributes to bexarotene induced-hypothyroidism.
Authors: Marcia I Dawson; Mao Ye; Xihua Cao; Lulu Farhana; Qiong-Ying Hu; Yong Zhao; Li Ping Xu; Alice Kiselyuk; Ricardo G Correa; Li Yang; Tingjun Hou; John C Reed; Pamela Itkin-Ansari; Fred Levine; Michel F Sanner; Joseph A Fontana; Xiao-Kun Zhang Journal: ChemMedChem Date: 2009-07 Impact factor: 3.466
Authors: Jennifer S Janssen; Vibha Sharma; Umarani Pugazhenthi; Celia Sladek; William M Wood; Bryan R Haugen Journal: Mol Cell Endocrinol Date: 2011-03-31 Impact factor: 4.102